摘要
背景:紫杉醇于1993年获得批准,标志着萜类化合物在抗癌领域的广泛应用,在治疗难治性卵巢、乳腺癌和难治性卵巢癌方面仍具有重要意义。她的癌症。几十年来,其他突出的天然萜类化合物已成为现代乳腺癌药物治疗不可缺少的物质。然而,鉴于耐药性的快速演变,对需要细胞毒性化疗的晚期乳腺癌的治疗是一个主要的未得到满足的临床需要。因此,迫切需要有效的长效化疗药物. 目的:综述2012年1月1日至2016年12月31日期间天然萜类化合物的研究进展及其防治女性乳腺癌的机制。 结果:癌变是一个多步骤的过程,每一个阶段都表现出明显的表型变化。这次审查中记录的许多化学品被证明是非常重要的。体外和体内抑制不同乳腺癌细胞/肿瘤的增殖、迁移、抗凋亡、抑制肿瘤血管生成或转移。同时瞄准几个或所有这些癌症的进展可能是一种优势。据此,植物化物,如胸腺醌(8),肋古诺内酯(46),丹参酮IIA(132),雷公藤内酯醇(136),葫芦素B(179),细胞星形胶质(226)和番茄红素(238)引起了我们的注意。 结论:这些化合物有望克服乳腺癌的治疗失败。然而,尽管这些活动令人感兴趣,但还需要进一步的临床前研究。乳腺癌细胞/肿瘤模型的体外和体内研究。
关键词: 乳腺癌,抗癌,萜类化合物,致癌,乳腺癌治疗。
Current Medicinal Chemistry
Title:Natural Terpenoids Against Female Breast Cancer: A 5-year Recent Research
Volume: 25 Issue: 27
关键词: 乳腺癌,抗癌,萜类化合物,致癌,乳腺癌治疗。
摘要: Background: The approval of Taxol® in 1993 marked the great entrance of terpenoids in the anti-cancer area and this drug is still highly important in the treatment of refractory ovarian, breast and other cancers. Over decades, other prominent natural terpenoids have become indispensable for the modern pharmacotherapy of breast cancer. However, given the rapid evolution of drug resistance, effective treatments for advanced breast cancers requiring cytotoxic chemotherapy represent a major unmet clinical need. Therefore, innovative agents effective in long-term chemotherapy are urgently needed.
Objective: This review examines recent advances/research about natural terpenoids, and their mechanisms against female breast cancer over the period covering January 1st, 2012 to December 31st, 2016.
Results: Carcinogenesis constitutes a multistep process wherein each stage is characterized by distinct phenotypic changes. Numerous chemicals recorded in this review have been shown to significantly inhibit proliferation, migration, apoptosis resistance, tumor angiogenesis or metastasis in different breast cancer cells/tumours in vitro and in vivo. Targeting simultaneously several or all these aspects/steps of cancer progression could be an advantage. In line with this, phytochemicals such as thymoquinone (8), costunolide (46), tanshinone IIA (132), triptolide (136), cucurbitacin B (179), celastrol (226) and lycopene (238) had caught our attention.
Conclusion: These compounds appear to be promising to overcome breast cancer treatment failure. However, despite the interesting activities, additional preclinical investigations are needed in further breast cancer cell/tumor models in vitro and in vivo.
Export Options
About this article
Cite this article as:
Natural Terpenoids Against Female Breast Cancer: A 5-year Recent Research, Current Medicinal Chemistry 2018; 25 (27) . https://dx.doi.org/10.2174/0929867325666180214110932
DOI https://dx.doi.org/10.2174/0929867325666180214110932 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Insights for Drugs Developed for Phospholipase D Enzymes
Current Drug Discovery Technologies Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Antibacterial Peptides and Gastrointestinal Diseases
Current Pharmaceutical Design Damaged Proteins Bearing L-Isoaspartyl Residues and Aging: A Dynamic Equilibrium Between Generation of Isomerized Forms and Repair by PIMT
Current Aging Science Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents HGF and HGF Agonists, Expression in Wound and Potential Role in the Management of Wound Healing
Current Signal Transduction Therapy Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Eradicating the Roots: Advanced Therapeutic Approaches Targeting Breast Cancer Stem Cells
Current Pharmaceutical Design Green Tea Catechins: Proposed Mechanisms of Action in Breast Cancer Focusing on the Interplay Between Survival and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Potential Targets to Modulate Neutrophil Function in Inflammation
Mini-Reviews in Medicinal Chemistry Novel Substituted Quinazolines for Potent EGFR Tyrosine Kinase Inhibitors
Current Medicinal Chemistry